Equillium Inc at Jefferies London Healthcare Conference Transcript
Welcome, everyone. Welcome to day three Jefferies 2022 London Healthcare Conference. Next presenting company is Equillium. Representing the company is the CSO, Steve Connelly. Welcome.
Thanks, Roger, and thank you to everybody attending here today, and thank you for the conference organizers for the opportunity to present. So I'm just going to go over a few slides, hit the high points that I think are important to investors about Equillium, and then I know Roger wants to go into some Q&A.
So Equillium, we are a company developing novel immunotherapies for autoimmune and inflammatory diseases. We largely target autoimmune diseases where we think there's severe unmet medical need or pockets where we believe we can bring a best-in-class therapy.
There are customary forward-looking statements and of course, some additional information about a pending transaction to acquire Metacrine. You can find more information here.
So why don't we dive
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |